ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA (NYSE:ADCT)
Income Statement
-
Revenue
| 1 Year |
N/A
|
| 3 Years |
N/A
|
| 5 Years |
N/A
|
-
Gross Proft
| 1 Year |
N/A
|
| 3 Years |
N/A
|
| 5 Years |
N/A
|
-219.3M
Operating Income
| 1 Year |
-84%
|
| 3 Years |
-34%
|
| 5 Years |
N/A
|
-246.3M
Net Income
| 1 Year |
-111%
|
| 3 Years |
-40%
|
| 5 Years |
N/A
|
Currency: USD
| Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | ||
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue |
0
-
|
2
+105%
|
1
-37%
|
2
-
|
|
| Operating Income | |||||
| Operating Expenses |
(219)
|
(122)
|
(127)
|
(93)
|
|
| Selling, General & Administrative |
(77)
|
(14)
|
(9)
|
(8)
|
|
| Research & Development |
(140)
|
(106)
|
(118)
|
(85)
|
|
| Depreciation & Amortization |
(2)
|
(2)
|
(1)
|
(0)
|
|
| Operating Income |
(219)
-84%
|
(119)
+5%
|
(126)
-37%
|
(92)
-
|
|
| Pre-Tax Income | |||||
| Interest Income Expense |
(27)
|
2
|
3
|
2
|
|
| Non-Reccuring Items |
0
|
0
|
(0)
|
0
|
|
| Total Other Income |
1
|
2
|
0
|
0
|
|
| Pre-Tax Income |
(246)
-112%
|
(116)
+6%
|
(123)
-37%
|
(90)
-
|
|
| Net Income | |||||
| Tax Provision |
(0)
|
(1)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(246)
|
(116)
|
(123)
|
(90)
|
|
| Net Income (Common) |
(246)
-111%
|
(116)
+5%
|
(123)
-37%
|
(90)
-
|
|
Balance Sheet
514M
Assets
| 1 Year |
273%
|
| 3 Years |
24%
|
| 5 Years |
N/A
|
178M
Liabilities
| 1 Year |
572%
|
| 3 Years |
98%
|
| 5 Years |
N/A
|
336M
Equity
| 1 Year |
202%
|
| 3 Years |
10%
|
| 5 Years |
N/A
|
Currency: USD
| Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | ||
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Cash Equivalents |
439
|
116
|
139
|
263
|
|
| Cash Equivalents |
439
|
116
|
139
|
263
|
|
| Total Receivables |
1
|
1
|
2
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
1
|
|
| Other Receivables |
0
|
1
|
2
|
1
|
|
| Other Current Assets |
10
|
6
|
2
|
1
|
|
| Total Current Assets |
451
|
123
|
142
|
265
|
|
| PP&E Net |
5
|
6
|
2
|
1
|
|
| PP&E Gross |
5
|
6
|
2
|
1
|
|
| Accumulated Depreciation |
4
|
3
|
1
|
1
|
|
| Intangible Assets |
10
|
8
|
7
|
5
|
|
| Long-Term Investments |
48
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
|
| Total Assets |
514
+273%
|
138
-9%
|
151
-45%
|
272
-
|
|
| Liabilities | |||||
| Accounts Payable |
5
|
3
|
7
|
8
|
|
| Accrued Liabilities |
12
|
6
|
5
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
5
|
1
|
0
|
0
|
|
| Other Current Liabilities |
19
|
10
|
11
|
9
|
|
| Total Current Liabilities |
40
|
20
|
22
|
21
|
|
| Long-Term Debt |
37
|
4
|
0
|
0
|
|
| Other Liabilities |
101
|
3
|
2
|
2
|
|
| Total Liabilities |
178
+572%
|
27
+9%
|
24
+7%
|
23
-
|
|
| Equity | |||||
| Common Stock |
6
|
4
|
0
|
0
|
|
| Retained Earnings |
652
|
443
|
326
|
204
|
|
| Additional Paid In Capital |
981
|
550
|
452
|
452
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
|
| Total Equity |
336
+202%
|
111
-12%
|
126
-49%
|
249
-
|
|
| Total Liabilities & Equity |
514
+273%
|
138
-9%
|
151
-45%
|
272
-
|
|
| Shares Outstanding | |||||
| Common Shares Outstanding |
76.7M
|
76.7M
|
76.7M
|
76.7M
|
|
Cash Flow Statement
-168.7M
Operating Cash Flow
| 1 Year |
-39%
|
| 3 Years |
-31%
|
| 5 Years |
N/A
|
-2.8M
Capital Expenditures
| 1 Year |
-31%
|
| 3 Years |
4%
|
| 5 Years |
N/A
|
-171.5M
Free Cash Flow
| 1 Year |
-39%
|
| 3 Years |
-30%
|
| 5 Years |
N/A
|
Currency: USD
| Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | ||
|---|---|---|---|---|---|
| Operating Cash Flow | |||||
| Net Income |
(246)
|
(116)
|
(123)
|
(90)
|
|
| Depreciation & Amortization |
2
|
2
|
0
|
0
|
|
| Other Non-Cash Items |
64
|
0
|
(0)
|
0
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
|
| Cash Interest Paid |
2
|
0
|
0
|
0
|
|
| Change in Working Capital |
12
|
(7)
|
1
|
14
|
|
| Cash from Operating Activities |
(169)
-39%
|
(122)
0%
|
(121)
-62%
|
(75)
-
|
|
| Investing Cash Flow | |||||
| Capital Expenditures |
(3)
|
(2)
|
(2)
|
(3)
|
|
| Other Items |
(0)
|
(0)
|
(0)
|
(0)
|
|
| Cash from Investing Activities |
(3)
-26%
|
(2)
+10%
|
(3)
+23%
|
(3)
-
|
|
| Financing Cash Flow | |||||
| Net Issuance of Common Stock |
433
|
102
|
(0)
|
197
|
|
| Net Issuance of Debt |
62
|
(1)
|
0
|
0
|
|
| Cash from Financing Activities |
495
+392%
|
101
-
|
(0)
-
|
197
-
|
|
| Change in Cash | |||||
| Effect of Foreign Exchange Rates |
0
|
0
|
(0)
|
0
|
|
| Net Change in Cash |
324
-
|
(23)
+81%
|
(124)
-
|
119
-
|
|